We conducted a prospective , randomised , controlled , open-label , pilot clinical trial in 40 patients fulfilling two of the following three criteria for AHF : ( 1 ) left ventricular ejection fraction < 40 % , ( 2 ) acute pulmonary oedema or respiratory failure of predominantly cardiac origin requiring mechanical ventilation and ( 3 ) currently receiving vasopressor and/or inotropic support .